Gastro-intestinal Quality of Life After Metabolic Surgery for the Treatment of Type 2 Diabetes Mellitus
- 429 Downloads
Emerging evidence has shown that bariatric/metabolic surgery ameliorates type 2 diabetes (T2DM) in mildly obese patients (BMI < 35 kg/m2) but long-term data is inadequate. We investigated the change of the quality of life after metabolic surgery in not well-controlled T2DM patients with BMI < 35 kg/m2.
The quality of life was measured by the gastrointestinal quality of life index (GIQLI), a 36-item questionnaire divided into three domains of general health and one domain of specific gastro-intestinal symptoms, administered before operation, at 3, 6, and 12 months after surgery. A control group matched in age, gender, and BMI was recruited for comparison.
A total of 86 patients were enrolled, and the preoperative BMI and HbA1C (mean ± SD) were 30.7 ± 2.8 kg/m2 and 9.3 ± 2.1 %, respectively. At 1 year after surgery, the BMI and HbA1C were 24.3 ± 2.3 kg/m2 and 6.2 ± 1.1 %, respectively. There was a significantly improvement in all of the measures of glucose metabolism. Complete remission (HbA1C < 6.0 %) was achieved in 56 subjects (65 %) at 12 months. The GIQLI score was significantly impaired in T2DM patients before surgery compared with the control group. The GIQLI score significantly increased from 109.2 ± 20.0 to 116.1 ± 14.2 points 1 year after surgery. The patients had improvement in the three domains of general health (social, physical, and emotional function) without a difference with the normal control but deteriorated in the domain of specific symptoms. Most of the patients experienced symptoms including abdominal pain, bloating, flatulence, belching, abdominal noise, regurgitation, dysphagia, slow eating speed, nausea, bowel urgency, and incontinence after metabolic syndrome.
Health-related QOL improved dramatically after metabolic surgery for not well-controlled T2DM patients with BMI < 35 kg/m2, but patients might develop specific gastro-intestinal symptoms after surgery.
KeywordsType 2 diabetes Metabolic surgery Quality of life Gastro-intestinal symptoms
Conflict of Interest
All authors declare that they have no conflict of interest, and the study has not been supported by any grants.
Statement of Informed Consent
Informed consent was obtained from all individual participants included in the study.
Statement of Human and Animal Rights
For this type of study, formal consent is not required.
- 12.Dixon JB, OBrien PE. Play fair I. et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: I ramdomized controlled trial. JAMA 2008 299:316–323Google Scholar
- 18.Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33 Suppl 1:S62-9.Google Scholar
- 37.Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes. N Engl J Med. 2014. doi: 10.1056/NEJMoa1401329.
- 41.Wuslin LR, Jacobson AM, Rand LI. Psychosocial aspects of diabetic retinopathy. Diabetes are. 1998;21:1699–706.Google Scholar
- 42.Hanestand BR, Gruce M. To maintain quality of life and satisfactory metabolic control in type II diabetes patients. Qual Life Res. 1995;4:436–7.Google Scholar
- 45.Keinanen-Kiukaanniemi S, Ohinmaa A, Pajunpaa H, et al. Health iabet Med. 1996;13:382–8.Google Scholar